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ABSTRACT 
Melanoma, occurring as a rapidly progressive skin cancer, is resistant to current chemo- 
and radiotherapy, especially after metastases to distant organs has taken place. Most 
chemotherapeutic drugs exert their cytotoxic effect by inducing apoptosis, which, 
however, is often deficient in cancer cells. Thus, it is appropriate to attempt the targeting 
of alternative pathways, which regulate cellular viability. Recent studies of autophagy, a 
well-conserved cellular catabolic process, promise to improve the therapeutic outcome in 
melanoma patients. Although a dual role for autophagy in cancer therapy has been 
reported, both protecting against and promoting cell death, the potential for using 
autophagy in cancer therapy seems to be promising.  Here, we review the recent literature 
on the role of autophagy in melanoma with respect to the expression of autophagic 
markers, the involvement of autophagy in chemo- and immunotherapy, as well as the role 
of autophagy in hypoxia and altered metabolic pathways employed for melanoma therapy.  
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1. Introduction 
Autophagy is an evolutionally conserved cellular “self-eating” process through which 
cells digest their own cellular contents via the lysosomal machinery, thereby providing 
energy and building blocks for cell survival. Autophagy is not a static process, rather a 
dynamic one during which long-lived proteins and/or organelles are engulfed in a double-
membrane autophagosome, which then fuses with lysosomes or late endosomes in order 
to degrade the sequestered contents with lysosomal enzymes ［1］ (Fig. 1). 
Three major types of autophagy have been reported in mammalian cells, including 
macroautophagy, microautophagy, and chaperon-mediated autophagy. These types differ 
in the cytosolic targets to be degraded and in the involvement of lysosomes. Macro- and 
microautophagy sequester cellular contents, e.g. organelles, whereas chaperon-mediated 
autophagy targets only soluble, long-lived proteins. The topic of this review is 
macroautophagy, hereafter referred to just as autophagy. During macroautophagy, 
cellular elements are engulfed by an isolating membrane of nonlysosomal origin, 
probably originating in endoplasmic reticulum (ER) ［2,3］, which expands and seals to 
form autophagosomes. Fusion of autophagosomes with lysosomes facilitates the 
degradation by lysosomal enzymes ［4］. According to the organelle being degraded, 
autophagy can be further divided into mitophagy (selective for mitochondria), pexophagy 
(selective for peroxisomes), reticulophagy (selective for ER), and so on ［5］. 
Autophagy is a highly regulated process, in which the activities of autophagy-related 
(ATG) proteins are involved. They can be divided into 4 functional groups. ATG proteins 
which regulate the induction of autophagy include ATG1 or ULK1, ATG13 and ATG17. 
ATG proteins responsible for vesicle nucleation include ATG6 or Beclin 1 and ATG9. 
Other ATG proteins are involved in autophagosome formation, such as ATG5, ATG12 
and ATG8 or LC3 (Fig. 1). And, finally, there are ATG proteins responsible for the 
retrieval of autophagy related proteins that include ATG2, ATG9 and ATG18 ［6-9］.  
Besides ATG proteins, autophagy is also controlled by mammalian target of 
rapamycin (mTOR) and class I and class III phosphoinositide 3-kinase (PI3K) pathways. 
mTOR and class I PI3K act to inhibit autophagy, whereas the class III PI3K complex 
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induces autophagy. Therefore, pharmacological inhibitors of mTOR, e.g. rapamycin, 
activate autophagy (Fig. 1) ［6］. A dual effect of 3-MA on autophagy has been shown 
since its persistent blockage of class I PI3K induces autophagy, while a transient 
suppression of class III PI3K inhibits autophagy ［10］. Detailed descriptions of the 
molecules and/or pathways regulating autophagy have been reviewed elsewhere ［11, 
12］. 
Even if autophagy is primarily understood as a pro-survival mechanism, interactions 
between the regulators involved in autophagy and in apoptosis have been described. 
ATG5, a key regulator of autophagy required for autophagosome formation, has also 
been shown to be cleaved by calpain, translocated to the mitochondria, and to induce 
apoptosis ［13］.  Bcl-2, an anti-apoptotic protein, is shown also to interact with Beclin 
1, thereby inhibiting autophagy ［14］. LC3 has been shown to be involved in cigarette 
smoke-induced apoptosis in mouse lung epithelia through interaction with Cav-1 and 
FAS ［15］. 
Autophagy is induced by cellular stress factors such as nutrient deprivation, growth 
factor withdrawal, and hypoxia ［16］, though it maintains a basal level under normal 
physiological conditions in cells. Autophagy regulates cellular homeostasis by 
maintaining a balance of synthesis and degradation. It has also been found to be involved 
in development and differentiation ［17］, aging ［18］ and immunity ［11］. Both 
insufficient and excessive autophagy can lead to pathological conditions. Dysregulated 
autophagy has been implicated in diverse diseases, including infection ［11, 19］ , 
neurodegenerative diseases ［20, 21］, cardiovascular diseases ［22, 23］, metabolic 
diseases ［24-26］,   pulmonary diseases ［27-29］, and cancer ［30-32］.  
Emerging evidence indicates a context-dependent role of autophagy in cancer. On the 
one hand, autophagy has a tumor suppressive function by inhibiting the proliferation of 
precancerous cells ［33, 34］ , by removing damaged organelles, e.g. mitochondria, 
thereby decreasing the risk of genome instability ［30］ and by inducing senescence 
［35］. On the other hand, autophagy may promote tumor progression by providing 
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tumor cells with nutrients under the conditions of nutrient- and oxygen-shortage, typical 
of the tumor environment ［4］. Direct evidence linking autophagy to tumor suppression 
comes from the fact that certain ATG proteins, such as Beclin 1, UVRAG, and Bif-1, 
exhibit an anti-oncogenic function. Beclin 1, as the first ATG to be identified as a tumor 
suppressor, has been found to be monoallelically deleted in breast, ovarian and prostate 
tumors ［36-38］ . An interaction partner of Beclin 1, UVRAG induces autophagy, 
thereby suppressing proliferation and tumorigenicity of colon cancer cells ［39］. Bif-1, 
which has been found to join in the Beclin 1-UVRAG complex, prevents spontaneous 
tumor formation in a mouse model［40］. Furthermore, deletion of atg5 in mouse liver 
resulted in spontaneous tumor formation ［41］. Indirectly, oncogenic pathways often 
show an inhibitory effect on autophagy, e.g. activated PI3K, whereas tumor suppressor 
genes frequently have the capability to induce autophagy, e.g. PTEN ［42, 43］. 
In established tumors, however, autophagy is believed mainly to protect tumors cells 
from drug-induced stresses, thus promoting drug resistance. Here, we review recent 
publications, which seem to unveil a role for autophagy in melanoma cancer therapy. 
 
2. The expression of ATG proteins in melanoma specimens 
Preclinical studies have implicated a potential tumor suppressive function of 
autophagy in the initiation of tumor formation, but a protective role favoring tumor cell 
survival once the tumor has already formed ［30］. Due to the limitations of techniques 
for monitoring the autophagy status in vivo, the results about autophagy levels in tumors 
have been mainly elucidated with in vitro experiments: e.g. using cell lines 
overexpressing GFP-LC3 to monitor autophagosomes or detecting p62 degradation and 
LC3 lipidation via Western Blot to monitor autophagic flux ［44］. For developing 
small molecules targeting autophagy for clinical application, the importance of evaluating 
autophagy levels in patients is self-evident. Several, although not many publications, 
have described the level of autophagy in melanoma tumor specimens using 
immunostaining techniques to detect the expression of ATG proteins. However, the 
results obtained in these studies have varied, probably owing to the heterogeneity of the 
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melanoma tumors themselves and to the different staining protocols employed for 
assessing the level of autophagy.  
In 13 cases of superficially spreading melanomas, LC3 immunostaining (using a 
polyclonal antibody against LC3B from Abcam) exhibited a heterogeneous vesicular 
pattern in the cytoplasm, whereas normal melanocytes were only weakly LC3-positive 
［45］. In contrast, Miracco et al. described a moderate cytoplasmic staining of LC3 in 
normal melanocytes and benign nevi (BN). Additionally, they observed a heterogeneous 
LC3 expression pattern in melanomas, including radial growth phase (RGP), vertical 
growth phase (VGP), and metastatic melanomas, using an LC3B antibody obtained from 
Sigma ［46］. A large scale of study of autophagy in melanoma using tissue microarrays 
(TMA) containing primary melanomas (n=131) and unmatched metastases (n=250) 
showed a significantly higher level of LC3 expression in metastases than that in primary 
tumors (using the polyclonal LC3B antibody from Abcam) ［45］. In contrast to these 
findings, Miracco et al. showed a moderate density of fine LC3 positive punctae, but 
rarely a diffuse LC3 cytoplasmic expression in normal melanocytes. However, in 
dysplastic nevi (DN) and melanomas, the LC3 staining pattern was rather heterogeneous, 
ranging from almost undetectable to diffuse cytoplasmic and finally even to large LC3-
positive dots (LC3B antibody from Sigma) ［46］.  
Besides LC3, Beclin 1 was also examined in melanoma specimens in some studies. 
For example, in normal melanocytes, BN and in the majority of DN, Beclin 1 exhibited a 
moderate-to-strong cytoplasmic staining and nucleolar positivity. In melanomas, Beclin 1 
expression seemed decreased with disease progression from RGP melanomas to 
metastases (Beclin 1-specific antibody from Santa Cruz was used for this study) ［46］, 
suggesting a tumor suppressive function of autophagy in melanoma. Consistent with the 
results of Miracco et al., Hara et al. showed a high level of Beclin 1 in advanced 
melanoma, but a low expression in melanoma in-situ (Beclin 1 antibody from Santa 
Cruz), suggesting a stage-dependent character for autophagy in melanoma ［47］. A link 
between autophagy and clinical outcome of melanoma patients has been documented by 
Sivridis et al. They showed a diffuse and variably cytosolic expression of LC3 (LC3A 
antibody from Abgent) and Beclin 1 (antibody from Abcam) in 79 cases of nodular 
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melanomas. Low Beclin 1 expression was correlated with invasiveness, tumor ulceration, 
and a decrease in 5-year survival after surgery. Interestingly, high levels of Beclin 1 
expression were found in hypoxic areas in some melanoma specimens and its expression 
was linked to an increase in early deaths ［48］. Half of the specimens showed a strong, 
diffuse staining of LC3 with no focal or punctate pattern (LC3A antibody from Abgent
［46, 48］. Taken together, it seems that different LC3 antibodies, recognizing different 
LC3 isoforms (LC3A or LC3B), could lead to different results. 
Contradicting the studies described previously, Ma et al. examined autophagosomes 
with electron microscopy in melanoma tumor specimens from 12 patients enrolled on a 
phase II trial of temozolomide and sorafenib ［49］ . Patients, who had a median 
progression free survival (PFS) of less than 2 months, had a significantly higher number 
of autophagosomes in their tumor specimens than those who had a median PFS of 2 or 
more than 2 months. Furthermore, they found no clear correlation between autophagy and 
BRAF or NRAS oncogene mutations in the tumors ［49］. In spite of the divers or even 
contradictory results of these studies, a systematic and in-depth evaluation of autophagy 
status in melanoma seems to be called for, examining the expression of further ATG 
proteins in better defined patients’ samples. 
 
3. The dual role for autophagy in melanoma cells receiving treatment with 
chemotherapeutic drugs  
Most of our knowledge about autophagy in melanoma came from the studies on 
melanoma chemotherapy in relatively large number of publications. These data were 
based mostly on in vitro experiments using established melanoma cell lines to monitor 
autophagosome formation and/or autolysosome degradation in the presence of a variety 
of therapeutic agents (Table 1). 
 Autophagy as a protective mechanism against chemotherapy-induced melanoma cell 
death has been reported in several recent publications. For example, Marino et al. have 
shown that induction of autophagy following treatment with esomeprazole, a proton 
pump inhibitor, delayed melanoma cell killing. Esomeprazole treatment impaired the 
mTOR signaling in the earlier phase, followed later by a rapid induction of ROS leading 
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to cell death. Furthermore, knocking down ATG5 or Beclin 1 expression significantly 
increased the efficacy of esomeprazole-induced melanoma cell death, indicating a 
protective role of autophagy ［50］. Similarly, sanguilutine, which induces necroptosis 
in melanoma cells, triggered an autophagic response. Inhibition of autophagy with 3-MA, 
bafilomycin A1 (BafA1) or LY294002 in combination with sanguilutine resulted in 
significant reductions in melanoma cell viability ［51］. G-quadruplex ligand, with the 
capability to interfere with guanosine-rich DNA/RNA sequences such as telomeres, 
impairs tumor cell growth by direct interfere with the telomere architecture, but had no 
effect on cell viability of normal cells ［52］ . Interestingly, it was reported that 
autophagy induced by G-quadruplex ligand in melanoma cells was a consequence of 
drug-induced telomere uncapping, ATM-dependent DDR and transactivation of the 
cyclin-dependent kinase inhibitor 1A ［53］. More importantly, pharmacological and 
genetic inhibition of autophagy intensified drug-induced cytotoxicity in melanoma cells, 
suggesting that autophagy as a pro-survival mechanism contributed to the resistance of 
melanoma cells to the G-quadruplex ligand ［53］. Tumor cells are known to change 
their metabolism from oxidative phosphorylation to aerobic glycolysis, resulting in 
increased production of metabolic acids and, thereby, tumor acidosis ［54］. Marino et 
al. investigated the response of melanoma cells under acidic culture conditions in vitro 
and found a rapid inhibition of the mTOR pathway, leading to an induction of autophagy. 
Besides, the authors showed that inhibition of autophagy after knocking down ATG5 
expression reduced the survival of melanoma cells exposed to an acidic environment 
［54］.  
Contrary results showing autophagy assisting cytotoxicity as a cellular response to 
chemotherapeutic agents have also been described in the literature. Cysteamine, a 
degradation product of cysteine in vivo ［55］, increased the autophagosome formation 
in the early phase of the treatment, whereas it blocked the autophagic degradation in 
melanoma cells in a later phase. A synergetic effect of cysteamine and doxorubicin on 
cell killing was observed, which was, however, reduced by knocking down ATG5 
expression. Interestingly, a concentration-dependent response of melanoma cells towards 
doxorubicin in combination with cysteamine was observed, which, however, was absent 
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in melanoma cells knocked down for ATG5 expression ［56］. Similarly, Tomic et al. 
have shown that metformin, a widely used antidiabetic drug ［57］, induced cell cycle 
arrest after 24h, induced autophagy after 72h and finally induced a robust apoptosis after 
96h. Importantly, they showed that inhibition of autophagy caused by knocking down 
LC3 or ATG5 also reduced the pro-apoptotic and anti-proliferative effect of metformin, 
indicating that autophagy is indispensable for metformin-mediated cytotoxicity in 
melanoma cells ［58］. Another supporting report came from the study of terfenadine, 
an H1 histamine receptor antagonist, by Nicolau-Galmés et al. They showed that 
terfenadine induced ROS-dependent apoptosis in the presence of serum, whereas it 
induced ROS-independent cell death to an even higher degree in serum-free medium. 
Furthermore, they showed terfenadine induced autophagy in serum-free medium and 
concluded that knockdown of ATG7 partially prevented terfenadine-induced cytotoxicity 
［59］. These data again indicate that induction of autophagy may promote melanoma 
cell death induced by diverse cytotoxic compounds. A ROS-dependent activation of 
apoptosis and autophagy was shown in a study of the cytotoxic effect of polygonatum 
cyrtonema lectin (PCL), a mannose-binding lectin. The authors demonstrated that PCL 
treatment induced ROS production and p38-p53 activation leading to induction of both 
apoptosis and autophagy ［60］. But the role of autophagy in this context was not fully 
clarified.  
Moreover, certain drugs seem to have the ability to induce an autophagic cell death 
together with a minimal induction of apoptosis in melanoma cells. For example, JG-03-
14, a microtubule poison, has been reported to have a cytotoxic effect on melanoma cells 
both in vitro and in vivo due to the induction of autophagy. Treatment of cells with 
autophagy inhibitors, such as chloroquine (CQ) or BafA1 demonstrated a moderate 
cytoprotection from JG-03-14. These seemingly contradictory findings were due to the 
fact that JG-03-14 induced apoptosis once autophagy had been blocked ［ 61］ . 
Chemotherapeutic agents, like JG-03-14, whose cytotoxic effect is due to induction of 
autophagy, would be especially suitable for anti-cancer therapy, because most of the 
cancer cells are anyway apoptosis-resistant. Consistent with the observation that the 
inhibition of autophagy induced apoptosis, Lakhter and colleagues newly showed that CQ 
10 
 
promoted apoptosis in melanoma cells and inhibited melanoma tumor growth in vivo. 
The pro-apoptotic effect of CQ was due to its ability to stabilize a pro-apoptotic protein, 
PUMA, based on the observation that the transcription of PUMA remained unchanged 
upon CQ treatment and the protein stability was prolonged after exposure to a de novo 
protein synthesis inhibitor, cycloheximide in the presence of CQ. These authors also 
demonstrated that other agents affecting lysosomal pH, such as BafA1 and the lysosomal 
cathepsin inhibitor ALLN, had no effect on PUMA protein stability. Moreover, the 
protease inhibitors leupeptin and lactacystin did not inhibit the degradation of PUMA. 
These data suggested that the apoptotic effect of CQ on melanoma cells via stabilization 
of PUMA was independent of lysosomal pathways ［62］. A very interesting report on 
the photodynamic treatment of melanoma cells revealed apoptosis or autophagic cell 
death was dependent on the melanin content in melanoma cells. In this study, authors 
showed that 5-ALA, a photosensitizer used in photodynamic therapy, induced a p53-
dependent apoptosis in pigmented melanoma cells, whereas it caused an autophagy-
dependent, caspase-independent cell death in non-pigmented melanoma cells ［63］. 
In the studies mentioned above, autophagy had been evaluated by Western Blot 
analysis to detect the lipidation of LC3［50-54, 56, 58-60, 62］ or the degradation of 
p62 ［50, 56, 61, 62］. Autophagosomes were visualized by the punctate pattern of 
either endogenous LC3 staining or overexpression of LC3 coupled with GFP (GFP-LC3) 
［51, 53, 54, 56, 58, 59, 62］and MDC or acridine orange staining ［56, 60, 61］. In 
some studies, electron microscopy was used to detect the double-membrane structure of 
autophagosomes ［51, 54, 56, 58- 60, 61］. Compared with the problem of evaluating 
the autophagy status in melanoma specimens from patients in vivo, measuring autophagy 
levels in melanoma cell lines would seem to offer more and better alternative 
experimental approaches, all of which should be applied in order to better characterize 
the autophagy status in vitro. 
 
4. Involvement of autophagy in melanoma therapies targeting an altered metabolic 
profile in tumor cells 
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Targeted therapy against melanoma is undergoing intensive investigation to improve 
the outcome for patients. Recently, the development of BRAF inhibitors to target the 
V600E mutation has brought a new perspective in melanoma therapy, but drug resistance 
as an inevitable consequence still remains unsolved ［64, 65］ . Depending on the 
genetic background, tumor cells may differ in their requirements for essential amino 
acids for their survival ［66］. An altered metabolism is beneficial for the cancer cells; 
however, the demand for nutrients to support tumor growth is also increased in the 
neoplastic cells. In the center of the tumor, where the nutrient supply is often poor, 
autophagy as a catabolic process has been shown to be activated to ensure the survival
［66, 67］.  To take advantage of this consideration, several studies have been carried 
out to find an alternative therapeutic approach targeting autophagy and altered 
metabolism in melanoma therapy.  
In a study examining the response of melanoma cells towards deprivation of single 
amino acids, Sheen et al. have found that deprivation of leucine, but not other essential 
amino acids, resulted in apoptosis. Apoptotic cell death in melanoma cells could be 
partially rescued by the pan-caspase inhibitors Q-VD-OPH. Furthermore, the authors 
showed that leucine deprivation failed to induce autophagy in melanoma cells with 
hyperactivation of RAS-MEK pathway, although it induced autophagy in other tumor cell 
lines. In contrast to deprivation of all other amino acids leading to suppression of 
mTORC1 and activation of autophagy, mTORC1 activity was very poorly inhibited when 
leucine was deprived. Inhibiting autophagy by knocking down ATG1 or VPS34 (class III 
PI3K) expression in melanoma cells, or by applying the autophagy inhibitor, CQ, in 
tumor xenografts synergistically sensitized melanoma cells towards leucine-deprivation-
induced cell death ［68］. Another report by You et al., however, demonstrated that 
arginine deprivation in combination with the treatment with TRAIL induced an enhanced 
apoptotic cell death in melanoma cells, which are often argininosuccinate synthetase 
(ASS)-negative. Autophagy as a protective response to cellular stresses was induced 
when arginine was deprived in melanoma cells; however, treatment of cells with TRAIL 
activated caspase-8 leading to the cleavage of Beclin 1 and ATG5, thereby inhibiting the 
induction of autophagy. Caspase-8 inhibitor, which blocked the cleavage of Beclin 1 and 
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ATG5, was able to reverse the enhanced cytotoxicity by TRAIL in combination with 
arginine deprivation, suggesting that the cleavage of Beclin 1 and ATG5 by TRAIL was 
at least one of the mechanisms leading to the effective cell killing seen with this 
combination therapy ［69］.  
Contrasting to the studies showing that inhibition of autophagy is beneficial for 
melanoma cell killing under amino-acid-deprived-condition, it has been reported that CQ 
induced a rapid melanoma cell death in serum-free medium independent of autophagy, 
because this effect was not recapitulated with autophagy inhibitors or by knocking down 
LC3 ［ 70］ . Furthermore, the authors showed that CQ-induced cytotoxicity of 
melanoma cells in the absence of serum is due to induction of apoptosis and necrosis 
resulting from mitochondrial depolarization. The action of CQ on melanoma cell death 
was not due to inhibition of autophagy, rather to an interaction with lysosomes. The 
lysosomal acidification inhibitor BafA1 prevented CQ-induced cell death under serum-
deprived condition, just as the failure of blocking autophagy to enhance cell death. Thus, 
it seems that the lysosomal pathway, but not autophagy is essential in this process. 
Importantly, CQ potentiated the anti-tumor effect of calorie-restriction in mice ［70］, 
consistent with the previous findings that calorie-restriction increases the lifespan and 
reduces the incidence of numerous diseases, including cancer ［71, 72］. 
 
5. Hypoxia-induced autophagy in melanoma tumor progression 
Hypoxia as a common character of proliferating tumor cells has been shown to be able 
to induce autophagy in different cellular settings. For example, Naves et al. have recently 
shown that treatment with CoCl2, a hypoxia mimetic, induced autophagy in p53-mutated 
neuroblastoma cells. Pharmacological inhibition of autophagy enhanced apoptosis and 
cell death in this context ［73］. In colon adenocarcinoma, autophagy was shown to be 
increased once disease progressed. Autophagy levels correlated to the expression of HIF-
1α, a transcription factor regulating hypoxia; and this hypoxia-driven autophagy is 
commonly associated with early invasion and severely dysplastic adenoma ［74］.  
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In melanoma, several recent reports showed the relationship between hypoxia, 
autophagy, and tumor progression. In a melanoma mouse model, in which B16F10 
murine melanoma cells are injected subcutaneously, an accelerated proliferation and 
angiogenesis was demonstrated in beclin 1+/- mice compared with wild-type mice. This 
effect seen in beclin 1+/- mice was even more enhanced under hypoxic condition. Cells 
derived from beclin 1+/- mice expressed an elevated level of HIF-2α. These mice were 
compromised for hypoxia-induced autophagy, which was evidenced by increased 
autophagosome formation and induction of beclin 1 seen in the wild-type mice, 
suggesting melanoma tumors deficient for beclin 1 showed a pro-angiogenic phenotype 
associated with a hypoxic character ［75］. Interestingly, Noman et al. have shown that 
hypoxia impaired tumor cells towards CTL-mediated lysis due to induction of autophagy. 
Furthermore, B16F10 melanoma cells deficient for beclin 1, exhibited growth inhibition 
and increased tumor apoptosis in vitro. Applying hydroxychloroquine in mice bearing 
B16F10 melanoma tumor cells dramatically reduced tumor growth ［76］.  
Another study investigating the regulation of (PEDF), a member of the serine protease 
inhibitor superfamily with anti-angiogenic and anti-metastatic activity in melanoma cells, 
revealed that hypoxia reduced PEDF levels via induction of autophagy and subsequent 
degradation of PEDF through an autophagic pathway. The results pointed out the 
potential contribution of hypoxia-induced autophagy for melanoma metastasis ［77］. In 
human melanoma specimen, a link between autophagy and hypoxia has been shown by 
Sivridis et al. In their study to examine the expression of LC3, Beclin 1, HIF-1α, and 
HIF-2α in 79 nodular melanomas, the authors found that high Beclin 1 and LC3 
expression was correlated with hypoxia as indicated by HIF-1α and HIF-2α 
immunoreactivity ［78］. However, it was mentioned that the staining pattern of LC3 
was cytoplasmic diffuse rather than punctate ［78］, raising the question whether a high 
level of LC3 expression could reflect an increased level of autophagy. These results show 
the contrasting opinions regarding the role of hypoxia-induced autophagy in tumor 
development and progression that might be, at least partially, due to the different model 
systems used in described studies.   
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6. Targeting autophagy in combination with immunotherapy in melanoma cells 
Alternative to the chemotherapeutic drugs which represent the mainstream of 
melanoma cancer therapy, immunotherapy is indispensable in enhancing the immune 
response of melanoma patients to improve the therapeutic outcome. Recently, ipilimumab, 
a novel, targeted human immunostimulatory monoclonal antibody that blocks CTLA-4, 
has shown survival benefit for metastatic melanoma patients ［79］.  As mentioned 
above, autophagy plays an important role in immunity and inflammation ［11, 80］. In 
the context of immunotherapy, the involvement of autophagy is becoming more and more 
evident. For instance, Tormo et al. have identified the dsRNA mimic polyinosine-
polycytidylic acid as a novel autophagy inducer. Interestingly, naked polyinosine-
polycytidylic acid activated a transient response of IFN and other antiviral stress response 
factors, while it induced a sustained stress response program once packed with 
polyethylene imine (PEI) for delivery of the dsRNA to the cells. The stress program 
included a rapid autophagic response and a strong induction of apoptosis thereafter. 
Moreover, autophagy induced in the early phase of the treatment is not a bystander or a 
protective process. It rather acts as a promoting factor in the induction of melanoma 
cytotoxicity, based on the observation, that wild-type mouse embryonic fibroblasts 
(MEFs) were more sensitive to polyinosine-polycytidylic-acid-induced cell death than the 
atg5 knockout counterpart ［81］.  
A possible link between autophagy, apoptosis, and the immune response has been 
shown in melanoma cells treated with GA-DM, a natural triterpenoid derived from the 
medicinal mushroom Ganoderma lucidum ［ 82, 83］ . GA-DM induced an early 
autophagic response (3-6h) with increased expression of Beclin 1 and LC3 lipidation, 
followed by apoptosis in later stage (24h) of the treatment. Blocking autophagy with 3-
MA at early time points resulted in cell death, which was remarkably increased beyond 
12h of GA-DM treatment regardless of 3-MA. These data indicate a cellular protection 
through autophagy in the early phase and that an excessive autophagic level could trigger 
a subsequent death event. These authors further proved that the eventual cell death was 
due to induction of caspase-dependent apoptosis. Importantly, autophagy induced in the 
early phase of the GA-DM treatment upregulated the HLA class II molecules as well as 
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the expression of the lysosomal protein LAMP2 in melanoma cells. Western Blot 
analysis of HLA class II components indicated an activation of the HLA class II antigen 
processing machinery due to a significant increase in HLA-DR and HLA-DM proteins. 
Furthermore, blocking autophagy with 3-MA reduced CD4＋ T cell response towards 
antigens presented by GA-DM treated melanoma cells ［83］.  
Downregulation or even loss of MHC class I antigen expression occurs very often in 
tumor cells, profoundly impeding antitumor immunity ［84, 85］ . In contrast to a 
positive role of autophagy in MHC class II presentation ［86, 87］, a dual role of 
autophagy in the regulation of MHC class I antigen expression in B16 murine melanoma 
cells has been shown by Li et al. ［88］. Whether autophagy is a positive or a negative 
regulator of the MHC class I antigen expression is dependent on IFN-γ: in the presence of 
IFN-γ, autophagy upregulated the MHC class I antigen expression whereas it reduced 
MHC class I antigen expression in the absence of IFN-γ. The authors further showed an 
efficient CTL cytolysis at the early stage of B16 melanoma tumor progression, when 
IFN-γ level is high, while it was largely impaired in the later stage of the tumor formation 
with immune escape of the tumor cells ［88］. 
The proteins in the donor cells that are potentially accessible for cross-presentation are 
degraded either by proteasomal or autophagic pathways［11］, hence a reduction in 
autophagic levels in tumor cells would facilitate cross-presentation by host professional 
APCs. Surprisingly, Li et al. have recently shown that rapamycin and starvation, which 
induce autophagy, greatly increased the presentation of endogenous melanoma-specific 
antigen, gp100, by DCs with increased proliferation of CD8＋ T cells. An opposite effect 
on antigen presentation has been shown in melanoma cells treated with 3-MA, which 
inhibits the early initiation of autophagosome formation. Interestingly, NH4Cl, which 
prevents lysosome acidification and, thereby, the fusion of the autophagosome with the 
lysosome, augmented the cross-presentation by melanoma cells. These data indicated the 
biphasic role of autophagy in cross-presentation; in the early phase, autophagy is required 
for cross-presentation, whereas in the late phase it hinders. Down-regulation of the 
essential ATG proteins involved in the early phase of autophagy, such as Beclin 1 and 
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ATG12 in melanoma cells, significantly reduced cross-presentation. Moreover, authors 
showed that isolated autophagosomes are the carriers of the protein antigens from the 
tumor cells, implying a potential role for autophagy in tumor immunotherapy ［89］. A 
follow-up study by the same group further characterized Dribbles, the autophagosome-
enriched, defective ribosomal products (DRiPs)–containing blebs and revealed the 
mechanism by which the enhanced efficacy of Dribbles as tumor vaccine in the B16F10 
melanoma tumor model is achieved［90］.   
 
7. Concluding remarks 
As an ancient, cellular catabolic pathway, autophagy deserves to be investigated 
continuously and intensively in connection with the field of oncology, certainly including 
melanoma. Experimental data from increasing numbers of publications have given us 
confidence that autophagy is likely to represent an alternative target in melanoma cancer 
therapy in spite of the inconsistent and even contradictory findings reported in the 
literature (Fig. 2, Table 1). One important step, which is unavoidable, is to evaluate the 
autophagic levels in melanoma in vivo. The current strategy is either to detect the 
expression of autophagy-related marker proteins by immunohistology or to detect the 
double-membrane autophagosomes in melanoma specimens by electron microscopy. 
However, the reagents and the staining procedures should be standardized to avoid 
technical artifacts. Additionally, the cohort of melanoma patients with clinical 
annotations enrolled on the study should be sufficiently large to allow definitive 
conclusions. Similar to measuring the autophagic flux in cell lines in vitro, a kinetic 
analysis of e.g. autophagosome formation should be carried out using melanoma three 
dimensional cultures mimicking, at least to a certain extent, melanoma tumors in vivo.  
Given that mTOR and the PI3K have pleiotropic functions, the agents used to target 
these pathways are potent, but not specific enough in regulating autophagy. 
Unfortunately, but not surprisingly, the statement that inhibition of autophagy facilitates 
the cytotoxic effect of a given compound is largely based on studies with these inhibitors. 
Whether the increased efficacy of the cytotoxic compounds in combination with these 
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inhibitors is indeed due to inhibition of autophagy or other mechanisms, needs to be 
clarified. Genetic manipulation of ATG proteins should be considered as an alternative 
approach in addition to treatments with these inhibitors.  
The question whether autophagy supports pro- or anti-tumor formation in melanoma 
pathology still remains unsolved. Future studies to characterize the autophagic levels as 
well as the expression of ATG proteins in melanoma varying from primary to metastatic 
stage will hopefully enlighten us with respect to the role of autophagy in disease 
progression. In addition, such a role for melanoma cancer stem cells needs also to be 
considered in order to reduce the reoccurrence after conventional therapy, since 
autophagy is required to maintain the stemness of skin-derived precursors (SKPs) ［91］. 
Altogether, the road to unveiling the role of autophagy in melanoma cancer therapy is 
rugged, but hopeful. Basic researchers should bring strong evidence for the importance of 
autophagy and should collaborate closely with dermatologists and other clinicians to 
realize the potential of this field for effective anti-melanoma treatment.  
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Figure and table legends: 
Fig. 1. The autophagic pathway. Autophagy can be divided into 3 main steps: Initiation, 
elongation, and degradation steps. Autophagy is induced by signaling cascades involving 
mTOR, class I and class III PI3K (VPS34). The mTOR inhibits autophagy through 
inhibiting ATG1/ULK1. Class I PI3K activates mTOR, therefore inhibits autophagy. 
During the initiation step of autophagy a large protein complex, including Beclin 1, the 
class III PI3K, VPS34，ATG14L, and p150, is formed. Activation of this complex 
generates PI3P, facilitating the nucleation of autophagosomal membrane. Several 
interacting proteins which participate in this complex include positive factors, such as 
UVRAG, Bif-1, and AMBRA1, and the negative factor Rubicon. In the elongation step, 
two distinct ubiquitin-like conjugation systems are involved. The ubiquitin-like ATG12 is 
conjugated to ATG5 by the E1-like ATG7 and the E2-like ATG10 enzymes. The 
conjugated ATG5-ATG12 then forms a complex with ATG16L, which is required in the 
elongation of the autophagosome membrane. The main player in the second conjugation 
system is LC3, which is cleaved by the protease ATG4 to generate the LC3-I form. LC3-I 
is decorated with phosphatidylethanolamine (PE) with the help of E1-like ATG7 and E2-
like ATG3 forming the LC3-II form. Finally, in the degradation step, engulfed contents 
are degraded after the fusion of autophagosome with a lysosome. Chemical compounds 
which target the different regulators in the autophagic pathway are also indicated in the 
schema.  
 
Fig. 2. Targeting autophagy for improved melanoma cancer therapy. Depending on the 
autophagy level in melanoma and the contribution of autophagy to eliciting tumor cell 
death, either an inhibition or an induction of autophagy can be considered in combination 
with other conventional anti-melanoma therapies. These ideas are presented in simplified 
form in this schema.  
 
Table 1. Effects of autophagy-regulating drugs on chemotherapy-induced melanoma cell 
death. 
